ArticleJournal of the Egyptian National Cancer Institute2026
Real-world efficacy and safety of CDK4/6 inhibitors plus endocrine therapy in HR+/HER2 - metastatic breast cancer: a single-institution experience.
Nawal E Hussein et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.